Alumis Finalizes Strategic Merger with ACELYRIN
In a significant development, Alumis Inc. (Nasdaq: ALMS), a biopharma company specializing in innovative therapies for immune-mediated diseases, has officially completed its merger with ACELYRIN, Inc. This merger marks a pivotal moment for Alumis as it strengthens its position in the biopharmaceutical industry.
Details of the Merger
Under the terms of the agreement, shareholders of ACELYRIN will receive 0.4814 shares of Alumis common stock for every share of ACELYRIN they own. Following this transaction, ACELYRIN's common stock is no longer traded on the NASDAQ Global Select Market, signifying its integration into Alumis.
Comments from Leadership
Martin Babler, President, CEO, and Chairman of Alumis, expressed enthusiasm about the merger, stating, "We are thrilled to move forward with a strengthened financial position that enables us to expand our late-stage product pipeline. This union empowers us to focus on delivering groundbreaking treatments for patients in need." Babler highlighted that the merger secures a cash runway that extends well into 2027, allowing Alumis to steadily progress without compromising operational focus.
The Road Ahead: Enhancing the Pipeline
With the merger now complete, Alumis aims to leverage its combined resources to further its development of innovative therapies. The company is particularly focused on its late-stage portfolio that targets systemic immune-mediated disorders. Noteworthy products under development include ESK-001, an oral tyrosine kinase 2 inhibitor designed to treat conditions such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus.
Expanding Therapeutic Focus
In addition to ESK-001, Alumis is advancing A-005, focused on neuroinflammatory and neurodegenerative diseases, further broadening its therapeutic landscape. Moreover, the company is also developing lonigutamab, an innovative treatment administered subcutaneously for thyroid eye disease, along with other preclinical initiatives driven by a precision approach to therapy development.
Key Partnerships and Expert Advisors
The successful merger and ongoing development efforts are supported by a network of esteemed advisors. Morgan Stanley & Co. LLC acted as financial advisor for Alumis, while Cooley LLP provided legal counsel. On the other side, Guggenheim Securities, LLC was the financial advisor for ACELYRIN, supported by legal counsel from Fenwick & West LLP and Paul Hastings LLP.
About Alumis
Alumis is committed to redefining patient care within the biopharmaceutical landscape, utilizing a distinctive data analytics platform to inform its research and product development strategies. By harnessing this technology, Alumis is not only developing advanced therapies but also ensuring these innovations are tailored to improve health outcomes for patients across diverse immunology-related challenges. For more details about Alumis and its pioneering treatments, visit www.alumis.com.
Frequently Asked Questions
What does the merger between Alumis and ACELYRIN entail?
The merger allows each ACELYRIN shareholder to receive shares in Alumis, marking a new phase for the company as it integrates ACELYRIN's assets into its portfolio.
How will this merger impact Alumis's future?
This merger strengthens Alumis’s finances and expands its product pipeline, enabling them to continue developing next-generation therapies for patients with immune-mediated diseases.
What are some of the key therapies under development by Alumis?
Alumis is developing several innovative therapies including ESK-001 for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases.
Who are the advisors involved in the merger?
Morgan Stanley & Co. LLC and Guggenheim Securities, LLC served as financial advisors for Alumis and ACELYRIN, respectively, along with legal counsel from Cooley LLP and others.
What is Alumis's goal following the merger?
Alumis aims to enhance its clinical pipeline and deliver transformative therapies for patients, capitalizing on the strengths gained through this merger.
